JP2021513536A5 - - Google Patents
Info
- Publication number
- JP2021513536A5 JP2021513536A5 JP2020542822A JP2020542822A JP2021513536A5 JP 2021513536 A5 JP2021513536 A5 JP 2021513536A5 JP 2020542822 A JP2020542822 A JP 2020542822A JP 2020542822 A JP2020542822 A JP 2020542822A JP 2021513536 A5 JP2021513536 A5 JP 2021513536A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- composition according
- linker
- composition
- pharmaceutical
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077703A JP2023113648A (ja) | 2018-02-09 | 2023-05-10 | Ｅｄｂ標的化ｉｌ－１２組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18156141 | 2018-02-09 | ||
| EP18156141.6 | 2018-02-09 | ||
| EP18179313 | 2018-06-22 | ||
| EP18179313.4 | 2018-06-22 | ||
| PCT/EP2019/053136 WO2019154986A1 (en) | 2018-02-09 | 2019-02-08 | Edb targeting il-12 compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077703A Division JP2023113648A (ja) | 2018-02-09 | 2023-05-10 | Ｅｄｂ標的化ｉｌ－１２組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513536A JP2021513536A (ja) | 2021-05-27 |
| JPWO2019154986A5 JPWO2019154986A5 (https=) | 2022-01-31 |
| JP2021513536A5 true JP2021513536A5 (https=) | 2022-01-31 |
| JP7279054B2 JP7279054B2 (ja) | 2023-05-22 |
Family
ID=65268973
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542822A Active JP7279054B2 (ja) | 2018-02-09 | 2019-02-08 | Ｅｄｂ標的化ｉｌ－１２組成物 |
| JP2023077703A Pending JP2023113648A (ja) | 2018-02-09 | 2023-05-10 | Ｅｄｂ標的化ｉｌ－１２組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077703A Pending JP2023113648A (ja) | 2018-02-09 | 2023-05-10 | Ｅｄｂ標的化ｉｌ－１２組成物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US12173044B2 (https=) |
| EP (1) | EP3749372B1 (https=) |
| JP (2) | JP7279054B2 (https=) |
| KR (2) | KR102259085B1 (https=) |
| CN (1) | CN111683687B (https=) |
| AU (2) | AU2019219201B2 (https=) |
| BR (1) | BR112020012888A2 (https=) |
| CA (1) | CA3087488C (https=) |
| CL (1) | CL2020002052A1 (https=) |
| CO (1) | CO2020009737A2 (https=) |
| CR (1) | CR20200342A (https=) |
| CU (1) | CU20200054A7 (https=) |
| EC (1) | ECSP20047171A (https=) |
| ES (1) | ES3035714T3 (https=) |
| IL (1) | IL275713A (https=) |
| JO (1) | JOP20200193A1 (https=) |
| MX (1) | MX2020008231A (https=) |
| MY (1) | MY200700A (https=) |
| PE (1) | PE20210122A1 (https=) |
| PH (1) | PH12020551230A1 (https=) |
| RU (2) | RU2758143C1 (https=) |
| SG (1) | SG11202006334XA (https=) |
| TW (1) | TWI844524B (https=) |
| UY (1) | UY38074A (https=) |
| WO (1) | WO2019154986A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI844524B (zh) * | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
| EP3856763A1 (en) | 2018-09-28 | 2021-08-04 | Massachusetts Institute of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
| CA3150224A1 (en) | 2019-09-10 | 2021-03-18 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| US20230312726A1 (en) * | 2020-04-14 | 2023-10-05 | Philogen S.P.A. | Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin |
| KR102649794B1 (ko) * | 2020-10-19 | 2024-03-22 | 고려대학교 산학협력단 | 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법 |
| AU2023206004B2 (en) * | 2022-01-04 | 2025-04-17 | Philogen S.P.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
| CN118359730A (zh) * | 2023-01-17 | 2024-07-19 | 上海君赛生物科技有限公司 | 包含细胞因子的靶向型融合蛋白 |
| WO2025061801A1 (en) | 2023-09-19 | 2025-03-27 | Philochem Ag | Therapeutic combination of an anti-edb fibronectin domain antibody il2 or il12 fusion protein and a lutetium-177 radioconjugate |
| WO2025251110A1 (en) * | 2024-06-03 | 2025-12-11 | Selvax Pty Ltd | Anti-cd40 antibody il-2 fusion proteins |
| WO2026003203A1 (en) | 2024-06-27 | 2026-01-02 | Philogen S.P.A. | Combination of an immunocytokine comprising targeted il2 and a jak inhibitor |
| WO2026013184A1 (en) | 2024-07-10 | 2026-01-15 | Ac Immune Sa | Fusion protein peptide linkers and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
| JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
| ATE333900T1 (de) * | 2000-02-24 | 2006-08-15 | Philogen Spa | Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| CN100535013C (zh) | 2002-03-11 | 2009-09-02 | 菲洛根股份公司 | 应用抗体分子对肿瘤血管进行选择性定向 |
| AU2005203962C1 (en) * | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| ATE459648T1 (de) | 2005-05-11 | 2010-03-15 | Philogen Spa | Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12 |
| US8580267B2 (en) * | 2008-12-19 | 2013-11-12 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| ES2534085T3 (es) | 2009-08-17 | 2015-04-17 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| EP2736535B1 (en) * | 2011-07-27 | 2018-10-17 | Philogen S.p.A. | Il-12 immunoconjugate |
| AU2014257906A1 (en) * | 2013-04-26 | 2015-12-10 | Philogen S.P.A. | IL4 conjugated to antibodies against extracellular matrix components |
| SG11201802912PA (en) * | 2015-10-10 | 2018-05-30 | Intrexon Corp | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
| WO2018153865A1 (en) | 2017-02-24 | 2018-08-30 | Philogen S.P.A. | Immunoconjugates with optimized linkers and orientation |
| WO2018224550A1 (en) * | 2017-06-07 | 2018-12-13 | Philogen S.P.A | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |
| TWI844524B (zh) * | 2018-02-09 | 2024-06-11 | 義大利商費洛根公司 | 靶向edb之il-12組合物 |
-
2019
- 2019-02-01 TW TW108104259A patent/TWI844524B/zh not_active IP Right Cessation
- 2019-02-07 UY UY38074A patent/UY38074A/es not_active Application Discontinuation
- 2019-02-08 CA CA3087488A patent/CA3087488C/en active Active
- 2019-02-08 BR BR112020012888-0A patent/BR112020012888A2/pt not_active IP Right Cessation
- 2019-02-08 SG SG11202006334XA patent/SG11202006334XA/en unknown
- 2019-02-08 PE PE2020001190A patent/PE20210122A1/es unknown
- 2019-02-08 RU RU2020127719A patent/RU2758143C1/ru active
- 2019-02-08 JP JP2020542822A patent/JP7279054B2/ja active Active
- 2019-02-08 WO PCT/EP2019/053136 patent/WO2019154986A1/en not_active Ceased
- 2019-02-08 CU CU2020000054A patent/CU20200054A7/es unknown
- 2019-02-08 MX MX2020008231A patent/MX2020008231A/es unknown
- 2019-02-08 AU AU2019219201A patent/AU2019219201B2/en active Active
- 2019-02-08 CN CN201980012247.6A patent/CN111683687B/zh active Active
- 2019-02-08 ES ES19702649T patent/ES3035714T3/es active Active
- 2019-02-08 JO JOP/2020/0193A patent/JOP20200193A1/ar unknown
- 2019-02-08 CR CR20200342A patent/CR20200342A/es unknown
- 2019-02-08 RU RU2021130306A patent/RU2021130306A/ru unknown
- 2019-02-08 MY MYPI2020002999A patent/MY200700A/en unknown
- 2019-02-08 US US16/968,445 patent/US12173044B2/en active Active
- 2019-02-08 KR KR1020207025138A patent/KR102259085B1/ko active Active
- 2019-02-08 KR KR1020217015607A patent/KR102488801B1/ko active Active
- 2019-02-08 EP EP19702649.5A patent/EP3749372B1/en active Active
-
2020
- 2020-06-28 IL IL275713A patent/IL275713A/en unknown
- 2020-08-06 CO CONC2020/0009737A patent/CO2020009737A2/es unknown
- 2020-08-06 EC ECSENADI202047171A patent/ECSP20047171A/es unknown
- 2020-08-07 PH PH12020551230A patent/PH12020551230A1/en unknown
- 2020-08-07 CL CL2020002052A patent/CL2020002052A1/es unknown
-
2021
- 2021-06-16 AU AU2021203986A patent/AU2021203986A1/en not_active Abandoned
-
2023
- 2023-05-10 JP JP2023077703A patent/JP2023113648A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513536A5 (https=) | ||
| RU2021130306A (ru) | Композиции il-12, нацеленные на edb | |
| RU2020114632A (ru) | Терапевтические способы, относящиеся к ингибиторам hsp90 | |
| KR20160072261A (ko) | 브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법 | |
| JP2018518454A5 (https=) | ||
| JPWO2020165734A5 (https=) | ||
| JP2016518387A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| JP2019520426A5 (https=) | ||
| JPWO2019154986A5 (https=) | ||
| TW202214243A (zh) | 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用 | |
| JPWO2022269525A5 (https=) | ||
| CN109985237A (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| JP2024016209A5 (https=) | ||
| JP2008500277A5 (https=) | ||
| Razak et al. | A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: ARA Razak et al. | |
| JP2020536048A5 (https=) | ||
| JP2024028756A5 (https=) | ||
| JPWO2021123996A5 (https=) | ||
| JP2018537433A5 (https=) | ||
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| JP2015510945A5 (https=) | ||
| Jin et al. | Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report | |
| WO2025033367A1 (ja) | 抗腫瘍剤併用療法 | |
| IL299028A (en) | Methods and compositions for treating chemotherapy-induced diarrhea |